Filgrastim (Indonesian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Filgrastim" in Indonesian language version.

refsWebsite

Global rank Indonesian rank

1^st place

2^nd place

4^th place

4^th place

13^th place

447^th place

792^nd place

195^th place

203^rd place

low place

dddmag.com

"FDA Reviews What Could Be First Biosimilar". Discov. Dev. Mag. Rockaway, New Jersey, United States. Associated Press. 25 July 2014. Diarsipkan dari versi asli tanggal 2014-07-29. Diakses tanggal 2016-09-22.

Beveridge, R. A.; Miller, J. A.; Kales, A. N.; Binder, R. A.; Robert, N. J.; Harvey, J. H.; Windsor, K.; Gore, I.; Cantrell, J. (1998). "A Comparison of Efficacy of Sargramostim (Yeast-Derived RhuGM-CSF) and Filgrastim (Bacteria-Derived RhuG-CSF) in the Therapeutic Setting of Chemotherapy-Induced Myelosuppression". Cancer Investigation. 16 (6): 366–373. doi:10.3109/07357909809115775. PMID 9679526.
Crawford, J.; Glaspy, J. A.; Stoller, R. G.; Tomita, D. K.; Vincent, M. E.; McGuire, B. W.; Ozer, H. (2005). "Final Results of a Placebo-Controlled Study of Filgrastim in Small-Cell Lung Cancer: Exploration of Risk Factors for Febrile Neutropenia". Supportive Cancer Therapy. 3 (1): 36–46. doi:10.3816/SCT.2005.n.023. PMID 18632435.

"FDA approves first biosimilar product Zarxio", FDA, March 6, 2015, diarsipkan dari versi asli tanggal 2018-01-26, diakses tanggal 23 November 2015

Beveridge, R. A.; Miller, J. A.; Kales, A. N.; Binder, R. A.; Robert, N. J.; Harvey, J. H.; Windsor, K.; Gore, I.; Cantrell, J. (1998). "A Comparison of Efficacy of Sargramostim (Yeast-Derived RhuGM-CSF) and Filgrastim (Bacteria-Derived RhuG-CSF) in the Therapeutic Setting of Chemotherapy-Induced Myelosuppression". Cancer Investigation. 16 (6): 366–373. doi:10.3109/07357909809115775. PMID 9679526.
Crawford, J.; Glaspy, J. A.; Stoller, R. G.; Tomita, D. K.; Vincent, M. E.; McGuire, B. W.; Ozer, H. (2005). "Final Results of a Placebo-Controlled Study of Filgrastim in Small-Cell Lung Cancer: Exploration of Risk Factors for Febrile Neutropenia". Supportive Cancer Therapy. 3 (1): 36–46. doi:10.3816/SCT.2005.n.023. PMID 18632435.

"FDA approves first biosimilar product Zarxio", FDA, March 6, 2015, diarsipkan dari versi asli tanggal 2018-01-26, diakses tanggal 23 November 2015
"19th WHO Model List of Essential Medicines (April 2015)" (PDF). WHO. April 2015. Diarsipkan (PDF) dari versi asli tanggal 2015-05-13. Diakses tanggal May 10, 2015.
"FDA Reviews What Could Be First Biosimilar". Discov. Dev. Mag. Rockaway, New Jersey, United States. Associated Press. 25 July 2014. Diarsipkan dari versi asli tanggal 2014-07-29. Diakses tanggal 2016-09-22.

"19th WHO Model List of Essential Medicines (April 2015)" (PDF). WHO. April 2015. Diarsipkan (PDF) dari versi asli tanggal 2015-05-13. Diakses tanggal May 10, 2015.